Market Snap Shot: Boeing Co (NYSE:BA)

The stock Earnings per share (EPS) and the diluted EPS are the profitability measures used in the fundamental analysis of companies. The figure of EPS only takes into account a Boeing Co (NYSE:BA)common shares, whereas the very important diluted EPS take into account all the convertible securities such as convertible bonds/convertible preferred stock, which are changed into equity or common stock. Dilutive effects occur when the number of shares increases, for example, through a new issue. If a company issues more shares to shareholders and other investors, this increases the number of shares outstanding and decreases the company’s earnings per share. Ultimately, this can decrease the stock price.Boeing Co (NYSE:BA) Diluted EPS is 17.48, whereas the EPS Estimate for next year is 22.51. The Annual EPS Growth of past 5 years is 24.50% and Boeing Co (NYSE:BA) yearly performance is 10.37% and net profit margin is 10.10%. 

Key Performance indicators for Boeing Co (NYSE:BA), in last 4 months the performance of BA was -4.56% while its price to sale ratio is 2.03 and price to book ratio is 1654.59. Company gross margin stands at 19.20% whereas its return on investment (ROI) is 76.40%. 

On 28 June 2019, Boeing Co (NYSE:BA), a Industrial Goods sector firm, traded 4.68 Million shares in last trading session and stock remains unchanged with closing price of $364.01 per share. with Boeing Co (NYSE:BA) traded 4.68 Million shares. The BA distance from 20 day simple moving average is 1.81% and distance from 50-Day simple moving average is 0.90%.The relative strength index for stock is 50.74 and Average true range of BA is 8.06. 

Analyst’s mean target price for BA is $420.33 while analysts mean recommendation is 2.30. The Stock value has moved between $293.56 – 443.91 in last one year. BA market capitalization is 204810.23 with beta of 1.31. Company has 0.10% insider ownership. 

Boeing Co (NYSE:BA) is under coverage by number of analysts. Stock has got OUTPERFORM rating from 9 of Thomson Reuters analysts, 7 given HOLD rating to the stock and 0 given UNDERPERFORM rating. Buy rating has been given by 8 analysts to the company stock. 

See also  Biotech Hot Stocks: Minerva Neurosciences Inc, SELLAS Life Sciences Group Inc., Array BioPharma Inc., Histogenics Corporation

Leave a Reply